´ëÇѹα¹ ¿¬±¸ÀںеéÀÇ µ¿¹ÝÀÚ°¡ µÇ°Ú½À´Ï´Ù. ´Ù¾çÇÑ ÆéŸÀÌµå ¶óÀ̺귯¸® Á¤º¸¸¦ °øÀ¯µå¸³´Ï´Ù.

ÇÏ´Ü¿¡ »ó¼¼¿µ¿ªº° Ä«Å×°í¸®¸¦ ´­¸£½Ã¸é º¸´Ù ½±°Ô ¿øÇÏ´Â Á¦Ç°À» ãÀ»¼ö ÀÖ½À´Ï´Ù. We will be your companion with our high technology and sufficent Know -how. If press below, You could easily find out several kinds of related informations.


Ä«Å×°í¸® Oligopeptide
CAT.NO
PRODUCT SFLLRN
Size
Price

Product name: SFLLRN

Sequence: Ser-Phe-Leu-Leu-Arg-Asn-NH2

Purity: 95% by HPLC

Counter ion: Trifluoacetate

Format: Lyophilized powder

Description: Protease-activated receptor-1 (PAR1) is activated by the cleavage of the extracellular N-terminal domain by proteases such as thrombin and plasmin. This cleavage releases a tethered ligand (SFLLRN) that activates the receptor and initiates a signaling cascade through G¥áq/11, G¥ái/o, or G¥á12/13 G-proteins. Free SFLLRN activates Protease-activated receptor-1 (PAR1) independent of receptor cleavage and has been used to probe PAR1 function in various cells and tissues.  SFLLRN-NH2-induced increases in astrocytic and neuronal calcium signals are blocked when the cells are pretreated with the glial metabolic blocker, fluorocitrate. Protease-activated receptor 1 agonist SFLLRN induced latent TGF¥â1 activation and Smad3 phosphorylation in human gingival fibroblasts.



Usage: For Scientific Research Use Only, Not for Human Use.

 

Reference:

J Dent Res. 2016 Feb 24. pii: 0022034516634288.

Arterioscler Thromb Vasc Biol. 2016 Jan;36(1):189-97.

J Lab Clin Med. 2000 Jan;135(1):66-72.

Biochemistry. 1999 Feb 23; 38(8):2486-93.

Thromb Haemost. 1993 Dec 20;70(6):1019-23.

÷ºÎÆÄÀÏ

¸Þ´º´Ý±â

°ßÀû¹®ÀÇ

INQUIRY

¾Æ·¡ Ç׸ñ¿¡ ¸Â°Ô Á¤È®È÷ ÀÔ·ÂÇÏ¿© ÁֽʽÿÀ.